Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight became a viral sensation as type 2 diabetes medicine Ozempic kicked off the GLP-1 trend. Novo Nordisk A/S NYSE: NVO formulated a semaglutide treatment specially designed for obesity when they launched Wegovy in June of 2021. Eli Lilly & Co. NYSE: LLY launched its own GLP-1/GIP dual agonist treatment for obesity, ...